ArticleBiomolecules & biomedicine2026
Survival outcomes and prognostic nomogram for primary pulmonary MALT lymphoma and diffuse large B-cell lymphoma: A SEER database study.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pulmonary lymphoma is a rare extranodal malignancy, and robust population-based evidence regarding its treatment and outcomes remains limited. This study aimed to compare treatment patterns and survival outcomes between primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma and primary pulmonary diffuse large B-cell lymphoma (DLBCL), as well as to develop an individualized prognostic model for pulmonary DLBCL. Patients diagnosed between 2010 and 2022 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression were employed to compare survival outcomes and identify prognostic factors. Additionally, a nomogram was constructed and internally validated for DLBCL. Among the 2,343 patients analyzed, 1,427 had MALT lymphoma and 916 had DLBCL. MALT lymphoma was more frequently managed with surgical intervention, while chemotherapy was more commonly utilized for DLBCL. After PSM, 441 matched pairs were analyzed, revealing that MALT lymphoma was significantly associated with better overall survival (OS) and cancer-specific survival (CSS) compared to DLBCL, with median OS of 131 months versus 68 months, respectively (p < 0.001). In patients with DLBCL, age ≥60 years emerged as an independent adverse prognostic factor, whereas surgical intervention and chemotherapy were independently associated with improved OS and CSS. The nomogram demonstrated moderate discrimination and good calibration in predicting 1-, 3-, and 5-year survival. These findings underscore that histological subtype is a critical determinant of prognosis in primary pulmonary lymphoma. The proposed nomogram may facilitate individualized prognostic assessments in pulmonary DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.